Investing IdeasBrowse All StocksMarkets

Have your own idea? Try our Stock Screener

Header cover image

Taiwanese (TAIEX) Healthcare Sector Analysis

UpdatedJan 21, 2025
DataAggregated Company Financials
Companies215
  • 7D0.01%
  • 3M-4.4%
  • 1Y2.6%
  • YTD2.4%

Over the last 7 days, the Healthcare industry has dropped 2.0%, driven by declines in PharmaEssentia and Lumosa Therapeutics of 1.8% and 9.4%, respectively. Meanwhile, Caliway Biopharmaceuticals actually outperformed within the industry, gaining 6.3% in the last week. Over the last year, the industry has been flat overall. Earnings are forecast to grow by 34% annually.

Sector Valuation and Performance

Has the Taiwanese Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 21 Jan 2025NT$1.5tNT$246.2bNT$8.7b21.9x174.5x6.2x
Thu, 19 Dec 2024NT$1.5tNT$220.5bNT$7.3b21.9x198.4x6.6x
Sat, 16 Nov 2024NT$1.5tNT$239.2bNT$7.5b23.6x197.5x6.2x
Mon, 14 Oct 2024NT$1.5tNT$236.4bNT$6.8b24.5x225.5x6.4x
Wed, 11 Sep 2024NT$1.6tNT$236.4bNT$6.8b24.6x231.9x6.6x
Fri, 09 Aug 2024NT$1.5tNT$229.3bNT$3.6b26.6x422.4x6.7x
Sun, 07 Jul 2024NT$1.7tNT$228.8bNT$3.6b30x465x7.3x
Tue, 04 Jun 2024NT$1.5tNT$228.6bNT$3.9b26.7x384x6.6x
Thu, 02 May 2024NT$1.4tNT$228.8bNT$4.3b25.5x340.3x6.3x
Sat, 30 Mar 2024NT$1.5tNT$228.9bNT$7.2b25.6x202.4x6.4x
Mon, 26 Feb 2024NT$1.5tNT$225.8bNT$6.5b25.3x225x6.4x
Wed, 24 Jan 2024NT$1.4tNT$225.0bNT$5.9b24.9x232.4x6.1x
Fri, 22 Dec 2023NT$1.4tNT$224.7bNT$5.9b25.7x238.8x6.2x
Sun, 19 Nov 2023NT$1.4tNT$224.7bNT$6.7b25.1x207.9x6.2x
Tue, 17 Oct 2023NT$1.3tNT$225.3bNT$8.3b24.9x162.9x6x
Thu, 14 Sep 2023NT$1.4tNT$225.2bNT$8.2b25.5x167.2x6.1x
Sat, 12 Aug 2023NT$1.4tNT$223.9bNT$9.6b24.6x142.4x6.1x
Mon, 10 Jul 2023NT$1.4tNT$226.5bNT$11.5b25.6x124.3x6.3x
Wed, 07 Jun 2023NT$1.4tNT$226.1bNT$11.7b24.5x123.2x6.4x
Fri, 05 May 2023NT$1.5tNT$220.1bNT$12.0b25.2x123.7x6.8x
Sun, 02 Apr 2023NT$1.4tNT$221.6bNT$13.1b22.1x108.8x6.4x
Tue, 28 Feb 2023NT$1.4tNT$214.8bNT$13.6b21.5x106.1x6.7x
Thu, 26 Jan 2023NT$1.3tNT$214.5bNT$13.8b20.1x94.3x6.1x
Sat, 24 Dec 2022NT$1.3tNT$214.5bNT$13.9b20.2x94.6x6.1x
Mon, 21 Nov 2022NT$1.3tNT$214.5bNT$14.0b17x90.2x5.9x
Wed, 19 Oct 2022NT$1.2tNT$207.4bNT$10.8b18.9x108.6x5.6x
Fri, 16 Sep 2022NT$1.4tNT$207.4bNT$10.8b21.4x131.5x6.8x
Sun, 14 Aug 2022NT$1.2tNT$200.9bNT$10.4b21.9x119.5x6.2x
Tue, 12 Jul 2022NT$1.2tNT$199.0bNT$9.8b21.9x122.6x6x
Thu, 09 Jun 2022NT$1.2tNT$207.9bNT$10.7b22.2x112.2x5.8x
Sat, 07 May 2022NT$1.2tNT$206.0bNT$12.2b23.3x101.5x6x
Mon, 04 Apr 2022NT$1.3tNT$204.7bNT$12.3b23.6x103.2x6.2x
Wed, 02 Mar 2022NT$1.2tNT$202.0bNT$14.4b22.7x83.7x6x
Fri, 28 Jan 2022NT$1.1tNT$202.1bNT$14.1b21.8x79.8x5.6x
Price to Earnings Ratio

79.8x


Total Market Cap: NT$1.1tTotal Earnings: NT$14.1bTotal Revenue: NT$202.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Healthcare Sector Price to Earnings3Y Average 175.4x202320242025
Current Industry PE
  • Investors are relatively neutral on the Taiwanese Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 175x.
  • The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have declined 15% per year over the last three years.
  • Meanwhile revenues for these companies have grown 6.8% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Taiwanese Healthcare sector?

TW Market3.46%
Healthcare0.0098%
Healthtech6.34%
Life Sciences1.85%
Medical Equipment0.54%
Pharma0.46%
Healthcare Services0.092%
Biotech-1.08%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 147x.
    • It looks like they are confident that earnings will grow faster in the future than they have historically.
Forecasted Growth
  • Analysts are most optimistic on the Biotech industry, expecting annual earnings growth of 71% over the next 5 years.
  • This is better than its past earnings growth rate of 8.8% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 8.7% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6919 Caliway BiopharmaceuticalsNT$703.0012.3%
+NT$11.8b		237.2%PS2158.3x
6932 Mercury BiopharmaceuticalNT$15.7038.3%
+NT$1.8b		-11.5%PS1150.4x
6472 Bora PharmaceuticalsNT$818.001.5%
+NT$1.2b		22.8%PE21.7x
6491 PegavisionNT$372.004.3%
+NT$1.2b		-1.1%PE14.5x
6620 Handa PharmaceuticalsNT$78.2011.2%
+NT$1.1b		-55.3%PE24.4x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlans & PricingLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

6472

NT$818.00

Bora Pharmaceuticals

7D

1.5%

1Y

22.8%

6541

NT$69.40

Tanvex BioPharma

7D

8.8%

1Y

6.6%

6931

NT$72.50

Qing Song HealthLtd

7D

-18.1%

1Y

-14.0%

What You Can Learn From Qing Song Health Co.,Ltd.'s (TWSE:6931) P/S After Its 26% Share Price Crash

Jan 17
What You Can Learn From Qing Song Health Co.,Ltd.'s (TWSE:6931) P/S After Its 26% Share Price Crash

6932

NT$15.70

Mercury Biopharmaceutical

7D

38.3%

1Y

-11.5%

6919

NT$703.00

Caliway Biopharmaceuticals

7D

12.3%

1Y

237.2%

6446

NT$696.00

PharmaEssentia

7D

-3.3%

1Y

115.8%

4142

NT$21.70

Adimmune

7D

-8.4%

1Y

-30.2%

There's No Escaping Adimmune Corporation's (TWSE:4142) Muted Revenues Despite A 26% Share Price Rise

Jan 13
There's No Escaping Adimmune Corporation's (TWSE:4142) Muted Revenues Despite A 26% Share Price Rise

1786

NT$123.00

SciVision Biotech

7D

8.4%

1Y

61.4%

SciVision Biotech Inc.'s (TWSE:1786) 25% Share Price Surge Not Quite Adding Up

Jan 13
SciVision Biotech Inc.'s (TWSE:1786) 25% Share Price Surge Not Quite Adding Up

4147

NT$84.70

TaiMed Biologics

7D

-3.0%

1Y

-2.2%

6535

NT$234.50

Lumosa Therapeutics

7D

-10.3%

1Y

104.8%

6620

NT$78.20

Handa Pharmaceuticals

7D

11.2%

1Y

-55.3%

1795

NT$257.00

Lotus Pharmaceutical

7D

-2.5%

1Y

-7.1%

Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings

Dec 04
Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings

4123

NT$40.30

Center Laboratories

7D

-5.2%

1Y

-15.2%

4166

NT$36.35

Orient Pharma

7D

-8.1%

1Y

71.9%

6491

NT$372.00

Pegavision

7D

4.3%

1Y

-1.1%

Impressive Earnings May Not Tell The Whole Story For Pegavision (TWSE:6491)

Nov 06
Impressive Earnings May Not Tell The Whole Story For Pegavision (TWSE:6491)

6696

NT$143.50

Lin BioScience

7D

9.5%

1Y

32.9%